<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231422</url>
  </required_header>
  <id_info>
    <org_study_id>BRAND-003</org_study_id>
    <nct_id>NCT04231422</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Top Evaluate a Novel Penile Lengthening Protocol</brief_title>
  <official_title>A Proof of Concept Top Evaluate a Novel Penile Lengthening Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Judson Brandeis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrandeisMD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine and quantify the efficacy and safety of a new&#xD;
      treatment protocol using platelet-rich plasma for penile length enhancement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">July 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stretched penile length</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Change in length of stretched, flaccid penile length</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SHIM Score</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Change in erectile function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDD-YBOCS</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Change in body dysmorphia scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Measurement</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Incidence of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Penile Elongation</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <description>Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Platelet-rich plasma</intervention_name>
    <description>12mL of platelet-rich plasma injected into cavernosal bodies bilaterally</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants comprised of men with a desire for penile elongation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stretched penile length between 3.5 - 8.0 in&#xD;
&#xD;
          2. Age 20-55 years of age&#xD;
&#xD;
          3. Desire penile length elongation&#xD;
&#xD;
          4. Willing to complete all aspects of combined treatment plan&#xD;
&#xD;
          5. Able to measure erect penile length and mid-shaft girth at 1-month intervals&#xD;
&#xD;
          6. Judged to be in good health based on medical history, physical exam, and laboratory&#xD;
             profile&#xD;
&#xD;
          7. Is willing and able to cooperate with the requirement of the study (e.g. completion of&#xD;
             all planned study visits)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No prior surgical Peyronie's disease treatment&#xD;
&#xD;
          2. No chordee with or without hypospadias&#xD;
&#xD;
          3. No infiltration by benign or malignant mass&#xD;
&#xD;
          4. No active STD&#xD;
&#xD;
          5. No infiltration by an infectious agent such as lymphogranuloma venereum&#xD;
&#xD;
          6. No uncontrolled psychiatric conditions&#xD;
&#xD;
          7. No uncontrolled neurologic conditions&#xD;
&#xD;
          8. No other uncontrolled medical conditions such as HTN or DM&#xD;
&#xD;
          9. No history of spontaneous priapism&#xD;
&#xD;
         10. Is unable to safely use the study devices as determined by the principal investigator&#xD;
&#xD;
         11. No thrombosis of the dorsal penile artery or vein&#xD;
&#xD;
         12. No known history of coagulation disorder&#xD;
&#xD;
         13. No known history of stroke, bleeding, or another significant medical conditional which&#xD;
             the investigator deems makes the subject unsuitable for enrollment in the study&#xD;
&#xD;
         14. Testosterone level lower than 500&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judson Brandeis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BrandeisMD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judson Brandeis, MD</last_name>
    <phone>510-587-3000</phone>
    <email>Judson@BrandeisMD.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BrandeisMD</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judson Brandeis, MD</last_name>
      <phone>510-587-3000</phone>
      <email>Judson@BrandeisMD.com</email>
    </contact>
    <investigator>
      <last_name>Scott Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>BrandeisMD</investigator_affiliation>
    <investigator_full_name>Judson Brandeis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>platelet-rich plasma</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

